ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more
ATAI Life Sciences BV (ATAI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.145x
Based on the latest financial reports, ATAI Life Sciences BV (ATAI) has a cash flow conversion efficiency ratio of -0.145x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.26 Million) by net assets ($159.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ATAI Life Sciences BV - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how ATAI Life Sciences BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ATAI Life Sciences BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ATAI Life Sciences BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinochem International Corp
SHG:600500
|
0.046x |
|
Zhejiang Windey Co Ltd
SHE:300772
|
0.144x |
|
Wilhelm Wilhelmsen Holding ASA
LSE:0P0T
|
0.009x |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
0.047x |
|
Energix - Renewable Energies Ltd.
PINK:ENREF
|
0.024x |
|
Seojin System Co.Ltd
KQ:178320
|
-0.054x |
|
GuoChuang Software Co Ltd
SHE:300520
|
0.007x |
|
Establishment Labs Holdings Inc
NASDAQ:ESTA
|
-0.688x |
Annual Cash Flow Conversion Efficiency for ATAI Life Sciences BV (2019–2024)
The table below shows the annual cash flow conversion efficiency of ATAI Life Sciences BV from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $116.55 Million | $-82.44 Million | -0.707x | -105.43% |
| 2023-12-31 | $244.32 Million | $-84.12 Million | -0.344x | +12.41% |
| 2022-12-31 | $265.77 Million | $-104.47 Million | -0.393x | -139.88% |
| 2021-12-31 | $385.96 Million | $-63.25 Million | -0.164x | +24.74% |
| 2020-12-31 | $95.37 Million | $-20.77 Million | -0.218x | -65.90% |
| 2019-12-31 | $59.78 Million | $-7.85 Million | -0.131x | -- |